This site uses cookies to store information on your computer. Learn more x

Study shows DSM’S geniVida® genistein can reduce levels of prostate specific antigen

Kaiseraugst, CH, 22 Sep 2011 12:00 CEST

geniVida® brand genistein from DSM Nutritional Products has been shown to reduce levels of prostate specific antigen (PSA) in men with early prostate cancer. The study was conducted by Bato Lazerevic and colleagues at the Oslo University Hospital in Oslo and was recently published in Nutrition and Cancer, 1-10, 2011.

In Asian countries where diets include high soy consumption, the incidence and mortality of prostate cancer is significantly lower than in Western countries. Isoflavones, and specifically genistein, are considered to be the major components from soy responsible for this difference. To gain a better understanding of the role of genistein, Dr. Lazerevic and colleagues conducted a placebo-controlled, randomized, double blind study in 47 men with early prostate cancer and elevated PSA levels. PSA is present in small quantities in the serum of men with healthy prostates but the level tends to rise in the presence of prostate disorders, including prostate cancer.

The intention of the study was to determine if there were any measureable benefits resulting from supplementation with 30mg genistein per day, an intake that could also be achieved by consuming a soy-rich diet such as a traditional Japanese diet. Supplementation with 30mg of geniVida brand pure aglycone genistein, during a period of three to six weeks, was shown to reduce PSA values in serum. This daily dose of geniVida was well tolerated with no effects on hormone levels, such as testosterone. In addition, this supplementation lowered blood cholesterol levels. These findings could help to explain the reduced risk of prostate cancer in men consuming a diet high in soy products and the potential benefit of a 30mg per day geniVida dietary supplement for men.